Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 4/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1967552 | 0.81 | CYP3A4 (0.46) | ALDH1A1CYP2A6AREGLN2CYP11B1 | |
| SCHEMBL7112459 | 0.79 | GABRA1 (0.44) | ALDH1A1CYP2A6ARLMNAEGLN2 | |
| SCHEMBL21386557 | 0.79 | GRM5 (0.38) | ALDH1A1CYP2A6ARLMNAABCB11 | |
| SCHEMBL11938978 | 0.78 | CA12 (0.39) | ALDH1A1ARABCB11NR3C1CYP1A2 | |
| SCHEMBL11554956 | 0.78 | KIF11 (0.34) | ALDH1A1EGLN2CYP11B1CYP11B2ABCB11 | |
| SCHEMBL7120694 | 0.78 | VCAM1 (0.39) | ALDH1A1ARLMNAEGLN2CYP11B1 | |
| SCHEMBL25918967 | 0.77 | APP (0.40) | ALDH1A1LMNAABCB11NR3C1CYP1A2 | |
| SCHEMBL28081371 | 0.77 | AR (0.49) | ALDH1A1AREGLN2CYP11B1CYP11B2 | |
| SCHEMBL7113859 | 0.77 | KIF11 (0.37) | ALDH1A1CYP2A6CYP1A2 | |
| SCHEMBL13952700 | 0.77 | ALDH1A1 (0.41) | ALDH1A1CYP2A6ARLMNAEGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475647-B1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | SUZHOU KINTOR PHARMACEUTICALS INC (CN) | 2015-11-04 | — | — | EP | disclosed |
| US-20140315957-A1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | TONG YOUZHI (CN) | 2014-10-23 | — | — | US | disclosed |
| US-8809550-B2 | Androgen receptor antagonists and uses thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2014-08-19 | — | — | US | disclosed |
| US-20120172406-A1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | Tong, Youzhi (CN) | 2012-07-05 | — | — | US | disclosed |
| WO-2011029392-A1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | TONG YOUZHI (CN) | 2011-03-17 | — | — | WO | disclosed |
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | DIXON BRIAN R (US) | 2003-11-06 | — | — | US | disclosed |
| US-6353006-B1 | TREATMENT OF BONE DISORDERS, OSTEOPOROSIS AND HEALING AGENT | BAYER CORPORATION | 2002-03-05 | — | — | US | disclosed |
| EP-1144396-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | Bayer Corporation (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042031-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172406-A1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | AR, SHBG, MUSK | ALDH1A1 786/4885CYP2A6 1105/4885AR 1/4885 |
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | PGR, PGRMC2, PGRMC1 | ALDH1A1 587/4885CYP2A6 182/4885AR 23/4885 |
| US-20140315957-A1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | AR, SHBG, MUSK | ALDH1A1 786/4885CYP2A6 1105/4885AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.